Research Helps Explain Idiosyncrasies of COVID-19

These are strange times we are living in, but hopefully the night is darkest just before the dawn.

---

Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is currently in practice with Skylands Medical Group, N.J.

References

1. Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033–1034.
2. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846–848.
3. McGonagle D, O’Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020 Jul;2(7):e437–e445.
4. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790–802.
5. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777–789.
6. Ten Cate H. Surviving COVID-19 with heparin? N Engl J Med. 2021 Aug 26;385(9):845–846. Erratum in: N Engl J Med. 2021 Sep 9;385(11):1056.
7. McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021 Mar;3(3):e224–e233.
8. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. 2020 Oct 23;370(6515):eabd4585.